Modality
Bispecific Ab
MOA
HPK1i
Target
BCMA
Pathway
Complement
SchizophreniaPSPFTD
Development Pipeline
Preclinical
~Feb 2018
→ ~May 2019
Phase 1
~Aug 2019
→ ~Nov 2020
Phase 2
~Feb 2021
→ ~May 2022
Phase 3
~Aug 2022
→ ~Nov 2023
NDA/BLA
Feb 2024
→ Jun 2029
NDA/BLACurrent
NCT03684148
1,971 pts·PSP
2024-02→2029-06·Terminated
1,971 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2029-06-093.2y awayPh3 Readout· PSP
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2029-06-09 · 3.2y away
PSP
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03684148 | NDA/BLA | PSP | Terminated | 1971 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1944 | Pfizer | NDA/BLA | APOC3 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| Adagratapinarof | Vertex Pharma | Preclinical | BCMA | |
| Bemanesiran | BioNTech | Phase 3 | PLK4 | |
| BII-5240 | Biogen | Phase 2/3 | MALT1 |